Trovafloxacin

Summary

Trovafloxacin (CHEMBL428) is an approved small-molecule antimicrobial agent (ATC J01MA13); indicated across 2 conditions including bacterial infectious disease and osteomyelitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01MA13
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 416.4 Da · C20H15F3N4O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL428
Name	Trovafloxacin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	62959
ChEBI	CHEBI:9763
ATC	J01MA13
Molecular formula	C20H15F3N4O3
Molecular weight	416.4
InChIKey	WVPSKSLAZQPAKQ-SOSAQKQKSA-N

SMILES: C1[C@@H]2[C@@H](C2N)CN1C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F

IUPAC name: 7-[(1R,5S)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid

ChEBI definition: A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 6-amino-3-azabicyclo[3.1.0]hex-3-yl substituents at positions 1, 6 and 7 respectively. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure.

Pharmacological roles (ChEBI): antimicrobial agent, hepatotoxic agent, topoisomerase IV inhibitor, DNA synthesis inhibitor, antibacterial drug.

Also known as: CP-99219, Trovafloxacin, Trovafloxacine, Trovafloxacino, Trovan, Turvel, trovafloxacin, Travafloxacin, TROVAFLOXACINE, TROVAFLOXACIN

Parent form; salt/anhydrous children: CHEMBL1200779

Patent coverage: 4,430 distinct patent families (17,587 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 17,417 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Thromboxane-A synthase, Retinoic acid receptor beta, Sodium-dependent dopamine transporter.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
TBXAS1	5.39	IC50	4023	nM	CHEMBL_ACT_7783720

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
osteomyelitis	0	MONDO:0005246	EFO:0003102

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00548002	Not specified	COMPLETED	Combination Therapy With Fluoroquinolone in Staphylococcus Aureus Bacteremia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).